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Obesity and ageing are both characteristics of the human population that are on the increase across the globe. It has long been
established that ageing is the major risk factor for neurodegenerative conditions such as Alzheimer’s disease, and it is becoming
increasingly evident that obesity is another such factor. Leptin resistance or insensitivity has been uncovered as a cause of obesity,
and in addition the leptin signalling system is less potent in the elderly. Taken together, these findings reveal that this molecule may
be a link between neurodegeneration and obesity or ageing. It is now known that leptin has beneficial eﬀects on both the survival
and neurophysiology of the neurons that are lost in Alzheimer’s disease suggesting that it may be an important research target in
the quest for strategies to prevent, halt, or cure this condition.
1. Introduction
It is a fact of life that as we age, changes occur to all
body systems. The outward phenotype of the elderly is
obvious with greying hair, wrinkling and thinning of the
skin, and a change in posture and the fluidity of move-
ment as joints and muscles stiﬀen. However, some of the
more devastating changes associated with ageing are often
hidden from the outside world, as neurological function
declines caused by the death of critical neuronal populations.
Neurodegenerative conditions arise when excessive neuronal
loss occurs within a discrete region of the nervous system.
Thus Parkinson’s disease (PD) is linked to the large scale
loss of neurons within the substantia nigra pars compacta,
and Alzheimer’s disease (AD) with degeneration in the
hippocampus and cerebral cortex. Loss of neuronal function
has a huge impact on the ability of an individual to interact
with their environment, whether through the lack of motor
control in PD, or though the decline in cognition, and as
a consequence of this, a full range of social interaction, in
AD. These changes aﬀect not only the suﬀerers, but also their
family and carers, and the whole of society, as the burden of
care falls onto national healthcare and social care systems.
The major risk factor for the development of neurode-
generative conditions is ageing. Therefore, as the human
population ages, it has been forecast that for dementia,
between the years 2001 and 2040, western countries will see a
100% increase in the number of individuals aﬄicted, with a
300% increase predicted for India and China [1]. Currently,
neurodegenerative conditions remain incurable. At the time
of writing, nearly 41 000 articles are cited within the pubmed
database for which neurodegeneration is a tagged search
term [2]. And yet from all this knowledge, no cures have
arisen. The reason for this is the complexity of the task of
curing a neurodegenerative condition. Firstly, the neurons
that have been lost need to be replaced, thereafter these
replacement cells need to make the correct connections with
other neurons and, if applicable, with target fields outside
the nervous system. The functionality of the neuronal
network must also be restored, and finally the replacement
neurons must be protected from the factors that triggered
neurodegeneration in the first instance, such that they too do
not undergo physiological decline and cell death. Given the
multistage process needed to cure a degenerative condition
within the nervous system, an easier target may be to find
strategies that prevent the occurrence of neurodegeneration
in the first place.
A plethora of risk factors, in addition to ageing, have been
identified that increase the incidence of neurodegenerative
diseases. These include a sedentary lifestyle [3], blows to the
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head (in the case of PD) [4], exposure to heavymetals such as
aluminium [5], elevated plasma levels of homocysteine [6],
and obesity [7], to name but a few. This review will focus on
obesity as a risk factor for the development of neurodegener-
ative conditions, in particular the loss of cognitive function
associated with Alzheimer’s disease and other dementias,
with an emphasis on the antiobesity hormone leptin.
2. Obesity and Dementia
Obesity is the excessive accumulation of fat within an
organism that may be caused by genetic factors, environ-
mental factors, or a complex interplay between the two. The
resulting energy imbalance between calories consumed in
the food, against calories expended in day to day living,
results in the excess nutrition being stored as fat. The World
Health Organisation estimated that in 2010 there were 300
million obese adults in the global population and 42 million
overweight children [8]. To clarify these figures further, it is
known that in developed countries, obesity aﬀects 25–30%
of adults [9, 10]. Furthermore, the incidence of obesity in the
elderly is rising. In a study of 65–74 year olds in the United
States, the rate of obesity increased from 27% in 1988 to
39% in 2000 [10]. These figures give us an indication of the
immense scale of the occurrence of obesity.
Investigations into a link between obesity and the onset
of dementia have been widely reported in the literature.
However, conflicting results have been presented. Thus,
a systematic review of published papers was undertaken,
and a definitive relationship between elevated body mass
index (BMI) and the incidence of dementia emerged [11].
Furthermore, it has been demonstrated that carriers of the
FTO allele have a slight increase in BMI as compared to
noncarriers. Interestingly, possession of this allele is also
linked to a decrease in brain volume in the healthy elderly
[12], linking elevated BMI to central nervous system changes.
It has also been established that there is a relationship
between an elevated waist to hip ratio and the risk of
developing a neurodegenerative condition [13], and that
advancing age and elevated BMI are linked to a decrease
in brain volume, but not cognition, in the middle aged
[14]. Similarly a decrease in grey matter volume has been
linked to adiposity in otherwise healthy postmenopausal
women [15]. However, these studies did not reveal the
underlying mechanisms that are activated by obesity, that
then lead to degenerative changes in the brain. Furthermore,
there is a lack of clarity in the published literature as to
whether being overweight or just being obese is a risk factor
for neurodegeneration and therefore further population-
based studies, coupled with rigorous laboratory-based tests
designed to tease out the underlying mechanisms linking
obesity to dementia, need to be carried out.
Just as the causes of neurodegeneration per se are mul-
tiple, complex, and likely to be interlinked, the causes of the
increased neurodegenerative risk induced by obesity are also
multiple and complex. Roles for lipotoxicity [16], diabetes
and insulin dysregulation or insensitivity [17, 18], and
erroneous synthesis or response to a number of circulating
factors have been postulated as potential mechanisms. It is
likely that all these factors and more are important in the
observed risk, but this review will solely focus on a potential
role for the antiobesity hormone leptin.
3. The Antiobesity Hormone Leptin
Leptin is the product of the ob gene, first cloned in 1994 [19].
Expression has been detected in adipose tissue, placenta,
the gastrointestinal system, and in a number of regions of
the central nervous system [19–22]. It is well established
that leptin plays a central role in the regulation of body
weight, reducing appetite and thus an inverse relationship
is established between plasma leptin levels and food intake
[23, 24]. The leptin receptor, Ob-R is widely expressed in the
body and is a member of the class I cytokine receptor family
[25]. Alternate splicing of Ob-R gives rise to six isoforms
(Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re, Ob-Rf) all of which
possess the extracellular leptin binding domain, but of which
only Ob-Rb has signalling competency, due to the possession
of the full intracellular domain [26–31].
Downstream of leptin binding to Ob-Rb, a number of
intracellular signalling pathways, can be triggered (Figure 1).
Ob-Rb does not possess intrinsic enzymatic activity and
therefore in order to transduce the signals initiated by leptin
binding, Janus kinase-2 (JAK-2) that is associated with Ob-
Rb, is autophosphorylated and activated [25, 32]. Thereafter
JAK-2 phosphorylates tyrosine residues within the Ob-Rb
intracellular domain to mediate the downstream eﬀects.
Each tyrosine (Tyr) that is phosphorylated triggers a unique
signalling event. As such, phosphorylation of Tyr985 leads
to the recruitment of Src-homology-2 (SH2)-containing
tyrosine phosphatase-2, triggering an extracellular signal-
regulated kinase (ERK) signalling cascade [33]. It is of
interest to note that mutagenesis of this tyrosine residue
leads to adult-onset obesity linked to leptin resistance in
mice [34]. Tyr1077 phosphorylation recruits and activates
the transcription factor signal transducer and activator of
transcription 5 (STAT5) [35], whilst STAT3 activation (and
to a lesser extent STAT5 activation) has been linked to
phosphorylation of Tyr1138 [33, 35]. Other signalling events
known to be triggered by the binding of leptin to Ob-Rb
include phosphatidylinositol 3-kinase (PI-3kinase), nuclear
factor kappa B (NF-κB) [36], and adenosine monophosphate
(AMP)-dependent protein kinase [37] activity although the
enzymatic pathways linking them to receptor activation
remain to be fully elucidated.
Expression of the leptin receptor has been described in
the brain, with transport of leptin into the brain believed
to be achieved by leptin binding to the short forms of
the receptor Ob-Ra and Ob-Rc that are present in the
choroid plexus and the microvasculature of the brain [26].
The signalling of leptin within the central nervous system
is believed to predominantly be via the full length Ob-Rb
form of the Ob receptor thereafter activating the signalling
pathways described in the previous paragraph. Expression of
Ob-Rb has widely been identified within the central nervous
system including the cortex and hippocampus that are the
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Figure 1: Signalling downstream of leptin binding to the Ob-R receptor. A number of pathways are activated. JAK-2-mediated
phosphorylation of Tyr985 on Ob-Rb activates SHP2 and subsequently ERK. Phosphorylation of Tyr1077 and to a lesser extent Tyr1138 activates
STAT5, whilst phosphorylation of Tyr1138 activates STAT3. Activation of STAT transcription factors leads to alterations in gene expression.
The biochemical pathways leading to activation of PI3kinase, AMPK, and mTOR when leptin binds Ob-Rb are less well characterised.
major site of neurodegeneration in AD and the substantia
nigra that is the major site of neuronal loss in PD [27, 30, 38].
To date there is very little known about regulation of the
leptin receptor under the specific circumstances of a given
neurodegenerative disorder, and this will clearly be a very
important area of research in the future. It is known that
both a deficiency in circulating leptin, as observed in leptin-
deficient animals, and an inability to respond to leptin, as
observed in animals with deficits in the Ob receptor, lead to
upregulation of Ob-Rb suggesting that there is close interplay
between levels of leptin detected and expression of the full
length receptor [39, 40].
A myriad of research has been conducted demonstrating
that leptin, coupled with a correct response to the hormone,
is central to the control of bodyweight and to other
physiological processes. Thus adipocyte-generated leptin acts
as a satiety signal inhibiting food intake [39] and in addition,
evidence suggests that leptin plays a key role in energy
expenditure. Thus, mice that fail to respond to leptin develop
obesity even if fed a diet that restricts calorific intake to
normal levels [41] implying that these animals are not
expending the energy from their food eﬃciently. Therefore,
a reduced ability to synthesise or respond to leptin is likely to
lead to a failure to control appetite and reduced expenditure
of energy, leading to an increase in weight and, in time,
obesity. In ob/ob mice, a loss of function mutation in the
ob gene that encodes leptin leads to obesity by around four
weeks of age [42]. Likewise db/dbmice or fa/fa rats that carry
a loss of function mutation in the Ob-R gene are obese by a
similar age [42]. It is therefore not surprising that failures
in the leptin signalling system have been linked to obesity
in humans [43–45]. Mechanisms by which this failure can
occur include deficits in leptin transport across the blood-
brain barrier, insuﬃcient leptin release and mutations in the
Ob-R receptor, or defects in its traﬃcking or downstream
signalling, preventing the correct response to the circulating
hormone [7].
4. Leptin and Neurodegeneration
Neurodegenerative diseases, as mentioned above, are char-
acterised by the loss of neurons in a specific region of the
nervous system and with abnormalities of neuronal function
in the cells that remain. It has been widely reported that
we face an increasing demographic shift across the globe
to an ageing population [46], which will bring about an
increase in the incidence of age-related neurodegeneration.
Given that we are also facing increasing levels of obesity
in the elderly [11], if there is a link between obesity and
neurodegeneration, then we need to know what it is and
how to deal with it. There is now a range of research data
published that reveals that leptin is one molecule that is
involved in linking obesity to neurodegeneration.
It has been demonstrated that aged rats have a lower
response to leptin as compared to young rats with decreased
signalling downstream of the Ob-R receptor identified as
a reason for this, and in particular a decrease in STAT3
activation has been noted with age [47]. In addition to
the age-linked reduced ability to respond to leptin, there
is also an age-linked decrease in the uptake of leptin by
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hypothalamic nuclei, which correlates to a decrease in Ob-
R expression [48]. Another mechanism that influences the
age-related decline in leptin responsiveness is an increase in
the levels of the suppressor of cytokine signalling-3 (SOCS-
3) that inhibits the transduction of the signals triggered
by leptin binding to Ob-R [49]. Thus, increased SOCS-3
expression has been identified in the aged hypothalamus
[50]. Similarly, enhanced hypothalamic levels of protein
tyrosine phosphatase 1B are believed to contribute to age-
related leptin resistance [51]. Thus, the elderly are less able to
respond to leptin for a variety of physiological reasons, which
raises the question of what this decrease in leptin signalling
might mean for neurons.
One of the physiological properties of leptin that is
central to its potential role in neurodegeneration is the
discovery that leptin can prevent neuronal death. Thus leptin
can protect cultured dopaminergic neurons from the central
nervous system, and trigeminal sensory neurons from the
peripheral nervous system, from cell death in response to a
number of diﬀerent stimuli [36]. In accordance with this it
has been noted that the brains of leptin-deficient mice are
of lower weight than their wild-type counterparts, perhaps
revealing that a lower number of neurons survive in these
animals [52]. In culturedmurine cortical preparations, leptin
can prevent excitotoxic neuronal loss triggered by NMDA.
Furthermore, systemically delivered leptin can prevent exci-
totoxic damage in vivo, reducing cortical lesions in mice
given high doses of ibotenate [53]. Neuroprotective roles
for leptin have also been found in animal models of stroke
where leptin administration protects against both oxygen-
glucose deprivation and middle cerebral artery occlusion
[54]. Similarly leptin is neuroprotective in both in vivo and
in vitro models of PD [36, 55], and it protects hippocampal
neurons in models related to epilepsy [56]. In the case of
AD, transgenic mice that exhibit neurodegeneration in brain
areas linked to AD have a marked reduction in the number
of dying neurons following treatment with a lentiviral
vector encoding leptin [57]. Taken together there is a large
body of evidence to suggest that leptin may be beneficial
in the prevention of neuronal death in neurodegenerative
situations.
In addition to neuronal death, conditions such as AD
are characterised by alterations in neuronal function. Thus,
leptin can modulate synaptic plasticity via enhancing N-
Methyl-D-aspartate (NMDA) receptor function [58, 59].
Given that synaptic plasticity is studied as the cellular basis
of memory formation, these findings raise the possibility that
leptin can have beneficial eﬀects on the memory loss that is
perhaps the best known symptom of AD. Thus rodents that
have mutations in Ob-R show memory impairment [60].
Furthermore, transgenicmice that exhibit deficits inmemory
and are used to model AD show a reduction in AD-linked
pathological changes and an enhancement in memory if
treated with exogenous leptin [61]. Whilst the discovery that
leptin can influence both memory and neuronal viability in a
laboratory setting strongly suggests that it may be important
in either the pathogenesis of or the treatment of AD, the case
for further study is only truly strengthened with human data.
Thus studies of the individuals that form the Framing-
ham cohort have revealed that decreased circulating leptin
levels are predictive of an increased risk of developing
dementia or AD [62]. In contrast to this, cross-sectional
studies have not revealed a link between leptin levels and
vascular dementia [63], and carriers of an Ob-R mutation
that reduces leptin binding do not have an enhanced risk of
AD [64]. Another study looked at vascular dementia and AD
in isolation. Once again this demonstrated a link between
low leptin levels and the development of AD when compared
to nondemented or vascular dementia patients. These latter
two groups had similar leptin levels. This study exhibits that
AD and vascular dementia [65], which are often grouped
together as disorders, may have a very diﬀerent pathogenesis
with regards to the action of this antiobesity hormone.
It is becoming increasingly evident that neuroinflamma-
tion is an important part of the pathology of neurodegenera-
tive conditions [66]. Thus, it is crucial to determine whether
leptin influences the activity or activation of the astrocytes
and microglia of the central nervous system. It has been
determined that glial cells may play a central role in synaptic
inputs into the hypothalamus and that leptin can influence
this process. It is particularly interesting to note that chronic
leptin administration leads to astrocyte activation suggesting
that the potential role of these cells inmodulating obesity and
neurodegeneration needs to be more extensively investigated
in the coming years [67].
5. Discussion
Articles in the press often highlight so-called “epidemics”
that it is believed will greatly impact upon the way that
healthcare and social care systems are organised as we move
forward in time. One of these issues that is frequently
mentioned is ageing, another is obesity. It is becoming
increasingly apparent in the scientific literature that a
common consequence of both of these so-called “epidemics”
is neurodegeneration. Thus, it is worthwhile to explore
whether there are shared mechanisms that link these two risk
factors to neurodegeneration with a view to preventing or
treating illnesses such as AD. Within this framework leptin
appears as one of the candidate molecules that might link
obesity and age to neurodegeneration.
It is clear that obesity increases with age and that one
of the reasons for this is that the way in which the body
responds to leptin changes with age. Thus there is a decrease
in circulating leptin [68], Ob-R, and in leptin uptake [48],
coupled with an increase in inhibitors of leptin signalling
[49–51]. It is well established that leptin is a satiety signal
and thus a decrease in the response to it will decrease
satiety, increasing energy intake and thus risking obesity.
It is also well documented that leptin has many beneficial
eﬀects on both neuronal survival and neurophysiology, thus
this decrease in leptin signalling in the elderly will have
a negative impact on the function of neuronal networks
that are sensitive to its eﬀects. Given that the hippocampus
has been long established to be fundamental to memory
processes that are lost in AD, the scientific evidence that
leptin is important for both the viability [56] and functioning
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[58, 59] of hippocampal neurons strongly suggests that leptin
may be important in the pathogenesis of AD. Coupled to this
is the finding from the Framingham cohort that low levels of
circulating leptin are a risk factor for the future development
of AD [62].
Since it is clear that leptin is a strong candidate as one of
the molecules that links obesity to neurodegeneration, and
we know that obesity in midlife enhances the risk of AD
[69], the possibility of manipulating leptin levels or leptin
signalling in advance of the onset of AD symptoms arises.
Thus as a preventative measure, adults with midlife obesity
could be assessed for their levels of, and response to, leptin
and strategies put in place to boost this signalling system.
In addition, restoring leptin function could have beneficial
eﬀects outwith the central nervous system including energy
homeostasis and neuroendocrine function [70]. However,
leptin is just one factor relating to obesity that may be
involved in AD pathogenesis. In addition to leptin, other
obesity-related factors are linked to AD including insulin
[18], changes to the cerebral vasculature [71], and direct
lipotoxicity [17]. In support of the notion that leptin may
not be a cure-all for all cases of dementia is the finding that
there is no correlation between leptin levels and vascular
dementia [63, 65]. Nonetheless, there is strong evidence
that leptin signalling has beneficial consequences for neural
networks, and therefore introducing corrective strategies in
individuals in whom this is compromised can only be of
benefit. Furthermore, given that leptin is only one of the links
between obesity and AD, any targeting of leptin signalling
in obese individuals who have leptin deficiency or reduced
sensitivity is likely to be most successful when combined
with lifestyle changes targeting a healthy weight and level
of activity. Of course it should also be emphasised that
individuals who exhibit a high level of leptin insensitivity
may be completely insensitive to leptin or leptin-derived
therapies if treatment is not carried out alongside therapies
to reverse this state of insensitivity.
There are good arguments to be put to promote leptin
and its downstream signalling pathways as possible drug
targets for not only the treatment of AD but also of other
neurodegenerative disorders [7, 72]. However, the ability of
leptin to protect against cell death is not universal, and it has
been demonstrated that leptin exerts neuroprotective eﬀects
on cerebellar Purkinje but not granule neurons in culture
[73]. It is therefore crucial to investigate leptin’s potential
therapeutic eﬀects extensively against each condition of
interest. As such a word of caution must be raised against
the current findings that imply that leptin is neuroprotective
in models of AD. There are numerous mice models for AD,
none of which provide a perfect recreation of the disease
pathology observed in human AD patients. For example,
although the Tg2576 transgenic mouse models do show the
glial-mediated inflammatory response and elevated levels of
Aβ and associated plaques that occur in the brains of AD
suﬀerers [74], there are other pathologies associated with AD,
such as neuronal loss and neurofibrillary tangles, that are not
displayed in this model. Thus leptin’s eﬀects must be robustly
tested in as many diﬀerent AD rodent and in vitro models as
possible before a definitive conclusion about how it might
confer neuroprotection can be drawn. This would also help
to elucidate where within the temporal progression of AD
leptin might confer the maximal benefits.
In this regard, leptin’s antiapoptotic actions would not
oﬀer any potential to cure AD. However, if given before
symptoms occur, leptin-targeting medicines could prevent
the loss of neurons associated with AD in the first instance.
It could also be targeted to early stage suﬀerers in order
to prevent further neuronal loss and therefore halt or slow
down disease progression. Another possible benefit of leptin’s
antiapoptotic abilities is in protecting grafted tissue, whether
from embryonic stem cells or fetal sources, once it is
transplanted into the suﬀerer. Grafting of host tissue has
been used with some success as a potential treatment for
PD but one of the problems with this therapy is that a large
number of the transplanted neurons degenerate within the
host. Thus for just one PD patient, tissue from between
9 and 12 embryos is required for bilateral implantation
[75]. For PD, interest has therefore turned to neurotrophins
that can enhance dopaminergic neuron number in grafted
tissue such as glial cell line-derived neurotrophic factor [76]
or, for tissue from early embryos, tumour necrosis factor
alpha (TNF-α) [77]. It is feasible therefore that leptin could
oﬀer neurotrophic support to grafted tissue in AD suﬀers
if technology advances to a point where such transplants
become a treatment option for this disease.
In addition to its antiapoptotic eﬀects, leptin has also
demonstrated beneficial eﬀects on memory [78]. Thus
leptin administration, again particularly early in disease
progression, may help to alleviate the alterations in synaptic
function associated with AD. There is a growing body of
evidence that synaptic alterations may precede neuronal
death in AD and therefore leptin’s eﬀects on these may
be central to allowing individuals to halt the decline in
memory function so strongly associated with AD. Thus
leptin exerts its beneficial eﬀects on the nervous system at
multiple levels from neuronal survival to synaptic plasticity,
suggesting that it could benefit AD suﬀerers in a number of
ways. Specifically it has been determined that leptin inhibits
hippocampal neurons, that are aﬄicted in AD, by activating
BK channels leading to the initiation of a PI3-kinase sig-
nalling cascade [79]. Furthermore, leptin can evoke NMDA-
receptor dependent-long-term depression under conditions
of enhanced excitability [80]. Thus electrophysiological data
suggests that leptin can enhance the cellular processes
thought to underpin memory formation.
One of the major benefits that leptin oﬀers as a potential
therapeutic target is that it is currently licensed for human
use as an antiobesity drug. The possession of this license
would markedly speed up the drug discovery pipeline [7].
Furthermore, we all produce leptin in our bodies as a
naturally occurring substance and as such it is well tolerated
in a therapeutic setting and few side eﬀects have been
identified following its use as an antiobesity agent. However,
leptin is not an easy drug to administer, and the current
treatment for obesity involves giving subcutaneous injections
of the drug. Pharmacological leptin has so far been given to
patients for peripheral metabolic disorders and to modulate
behaviours and endocrine pathways in the hypothalamus.
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Thus, it is unclear whether subcutaneous administration of
leptin could act on the hippocampus and cortex that are
aﬀected in AD. In rodents intranasal administration of leptin
successfully raises brain leptin levels, particularly in the
hypothalamus [81, 82]. Also, a nonreplicative, nonimmuno-
genic and non-pathogenic recombinant adeno-associated
virus encoding the ob gene has been used as a form of central
gene therapy by direct injection into the aﬀected brain area to
provide a stable supply of leptin in that region. This has been
used successfully to suppress weight gain in prepubertal rats
[83], to inhibit fat deposition [84], and to block high fat diet-
induced weight gain [85]. Thus, much important work still
needs to be carried out to reveal the most eﬀective method of
leptin delivery into regions of the brain in humans.
In conclusion, with an increasing elderly population and
an increasing rate of obesity within that population, it is
imperative that we fully understand the noted links between
obesity and neurodegeneration. Candidate molecules for
explaining this connection are being discovered all the time,
and it is within this framework that interest has turned to the
antiobesity hormone leptin. The multilevel beneficial eﬀects
that are reported for leptin in neurons give hope that we may
be on the road to uncovering pathways that can be targeted to
halt, prevent, and perhaps eventually cure neurodegenerative
disorders such as AD.
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